Nektar Therapeutics (NASDAQ:NKTR) Shares Acquired by Texas Permanent School Fund

Texas Permanent School Fund increased its stake in Nektar Therapeutics (NASDAQ:NKTRGet Rating) by 2.4% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 133,943 shares of the biopharmaceutical company’s stock after buying an additional 3,101 shares during the quarter. Texas Permanent School Fund owned about 0.07% of Nektar Therapeutics worth $509,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. First Trust Advisors LP boosted its holdings in Nektar Therapeutics by 28.4% during the first quarter. First Trust Advisors LP now owns 4,390,618 shares of the biopharmaceutical company’s stock valued at $23,665,000 after purchasing an additional 970,889 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Nektar Therapeutics by 5.0% during the first quarter. Vanguard Group Inc. now owns 19,430,385 shares of the biopharmaceutical company’s stock valued at $104,729,000 after purchasing an additional 918,474 shares in the last quarter. Candriam Luxembourg S.C.A. acquired a new stake in Nektar Therapeutics during the first quarter valued at approximately $3,697,000. Edgestream Partners L.P. boosted its holdings in Nektar Therapeutics by 1,457.7% during the first quarter. Edgestream Partners L.P. now owns 623,707 shares of the biopharmaceutical company’s stock valued at $3,362,000 after purchasing an additional 583,667 shares in the last quarter. Finally, PDT Partners LLC boosted its holdings in Nektar Therapeutics by 466.1% during the first quarter. PDT Partners LLC now owns 652,835 shares of the biopharmaceutical company’s stock valued at $3,519,000 after purchasing an additional 537,523 shares in the last quarter. 96.99% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

NKTR has been the topic of a number of recent research reports. StockNews.com initiated coverage on Nektar Therapeutics in a report on Wednesday, October 12th. They set a “hold” rating on the stock. JPMorgan Chase & Co. downgraded Nektar Therapeutics from a “neutral” rating to an “underweight” rating in a report on Monday, August 8th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $8.40.

Insiders Place Their Bets

In other Nektar Therapeutics news, insider Jonathan Zalevsky sold 13,460 shares of the company’s stock in a transaction on Wednesday, November 16th. The shares were sold at an average price of $3.57, for a total transaction of $48,052.20. Following the completion of the sale, the insider now owns 313,663 shares in the company, valued at approximately $1,119,776.91. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Nektar Therapeutics news, Director Karin Eastham sold 21,267 shares of the company’s stock in a transaction on Tuesday, September 13th. The shares were sold at an average price of $3.61, for a total transaction of $76,773.87. Following the completion of the sale, the director now owns 13,033 shares in the company, valued at approximately $47,049.13. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Jonathan Zalevsky sold 13,460 shares of the company’s stock in a transaction on Wednesday, November 16th. The shares were sold at an average price of $3.57, for a total transaction of $48,052.20. Following the sale, the insider now owns 313,663 shares of the company’s stock, valued at approximately $1,119,776.91. The disclosure for this sale can be found here. In the last quarter, insiders have sold 88,034 shares of company stock valued at $313,411. 3.38% of the stock is currently owned by corporate insiders.

Nektar Therapeutics Stock Performance

NASDAQ:NKTR opened at $3.36 on Tuesday. The stock’s fifty day moving average price is $3.53 and its two-hundred day moving average price is $3.80. Nektar Therapeutics has a 52-week low of $2.96 and a 52-week high of $15.94. The company has a market cap of $631.53 million, a price-to-earnings ratio of -1.38 and a beta of 1.24.

Nektar Therapeutics Profile

(Get Rating)

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19.

Featured Articles

Want to see what other hedge funds are holding NKTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nektar Therapeutics (NASDAQ:NKTRGet Rating).

Institutional Ownership by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.